These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani. Sharma A; Madhubala R J Immunol; 2009 Dec; 183(12):7719-31. PubMed ID: 19933862 [TBL] [Abstract][Full Text] [Related]
4. Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis. Jaiswal AK; Khare P; Joshi S; Kushawaha PK; Sundar S; Dube A PLoS One; 2014; 9(9):e108556. PubMed ID: 25268700 [TBL] [Abstract][Full Text] [Related]
5. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Melby PC; Yang J; Zhao W; Perez LE; Cheng J Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral Leishmaniasis. Kushawaha PK; Gupta R; Tripathi CD; Sundar S; Dube A PLoS One; 2012; 7(4):e35670. PubMed ID: 22539989 [TBL] [Abstract][Full Text] [Related]
7. Jamal F; Singh MK; Hansa J; Pushpanjali ; Ahmad G; Dikhit MR; Umar MS; Bimal S; Das P; Mujeeb AA; Singh SK; Zubair S; Owais M Front Immunol; 2020; 11():817. PubMed ID: 32582140 [TBL] [Abstract][Full Text] [Related]
8. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity. Choudhury R; Das P; De T; Chakraborti T Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Leishmania donovani disulfide isomerase as a potential target of cellular immunity against visceral leishmaniasis. Amit A; Chaudhary R; Yadav A; Suman SS; Narayan S; Das VN; Pandey K; Singh SK; Singh BK; Ali V; Das P; Bimal S Cell Immunol; 2014; 289(1-2):76-85. PubMed ID: 24732062 [TBL] [Abstract][Full Text] [Related]
10. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis. Das P; Paik D; Naskar K; Chakraborti T Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116 [TBL] [Abstract][Full Text] [Related]
11. LmjMAPK10 offers protection against Leishmania donovani infection. Kumar S; Zutshi S; Patidar A; Bodhale N; Roy S; Sarkar A; Saha B Parasite Immunol; 2020 Feb; 42(2):e12687. PubMed ID: 31770453 [TBL] [Abstract][Full Text] [Related]
13. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge. Kushawaha PK; Gupta R; Sundar S; Sahasrabuddhe AA; Dube A J Immunol; 2011 Dec; 187(12):6417-27. PubMed ID: 22079980 [TBL] [Abstract][Full Text] [Related]
14. Leishmania genome analysis and high-throughput immunological screening identifies tuzin as a novel vaccine candidate against visceral leishmaniasis. Lakshmi BS; Wang R; Madhubala R Vaccine; 2014 Jun; 32(30):3816-22. PubMed ID: 24814525 [TBL] [Abstract][Full Text] [Related]
15. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides. Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073 [TBL] [Abstract][Full Text] [Related]
16. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Bhowmick S; Ravindran R; Ali N Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029 [TBL] [Abstract][Full Text] [Related]
17. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis. Samant M; Gupta R; Kumari S; Misra P; Khare P; Kushawaha PK; Sahasrabuddhe AA; Dube A J Immunol; 2009 Jul; 183(1):470-9. PubMed ID: 19542458 [TBL] [Abstract][Full Text] [Related]
18. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803 [TBL] [Abstract][Full Text] [Related]
19. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. Basu R; Bhaumik S; Basu JM; Naskar K; De T; Roy S J Immunol; 2005 Jun; 174(11):7160-71. PubMed ID: 15905560 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections. Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]